Press releases

5 October, 2017

NeuroVive’s collaborator the Children’s Hospital of Philadelphia awarded NIH grant to study NVP015 against chemical threats

Lund, Sweden, 5 October 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF, the mitochondrial medicine company, today announced that its research collaboration partner the Childre ...

3 October, 2017

NeuroVive presents innovative metabolic regulators for NASH. Abstract selected as top tier at The Liver Meeting 2017

Lund, Sweden, 3 October 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that an abstract with new preclinical data related ...

21 September, 2017

Regulatory

NeuroVive receives positive EMA Scientific Advice on its NeuroSTAT development plan for TBI

Lund, Sweden, 21 September 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced positive feedback on its requested Scientific A ...

27 June, 2017

Regulatory

NeuroVive and Yungjin Pharm start clinical development in genetic mitochondrial disease

Lund, Sweden and Seoul, South Korea, 27 June 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) and Yungjin Pharm Corporation Ltd (South Korea Stock Market, KRX 003520) today ann ...

1 June, 2017

Regulatory

NeuroVive receives research grant from Vinnova for development of the NVP015 genetic mitochondrial disease project

Lund, Sweden, 1 June 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company receives close to 1 million SEK in a research grant from Swedish innovati ...

23 May, 2017

Regulatory

NeuroVive to continue NeuroSTAT® clinical development after positive outcome in preclinical and clinical TBI studies

Lund, Sweden, 23 May 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced positive results from clinical and preclinical studies with its drug NeuroSTAT® for the pr ...

2 May, 2017

Regulatory

NeuroVive in-licenses a genetic mitochondrial disease clinical stage project from Yungjin Pharm

Lund, Sweden and Seoul, Korea, 2 May 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) and Yungjin Pharm Corporation Ltd (South Korea Stock Market, KRX 003520) today jointly ann ...

27 April, 2017

Regulatory

Resolutions from Annual General Meeting in NeuroVive Pharmaceutical AB (publ)

Lund, Sweden, 27 April 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) ("NeuroVive") today on 27 April 2017 held its Annual General Meeting (AGM). A summary of the resolutions ...

20 April, 2017

Regulatory

NeuroVive Presents Preclinical Findings of NV556 in NASH Showing Confirmatory Anti-fibrotic Effects

Lund, Sweden, 20 April 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) ("NeuroVive") today announced positive preclinical results demonstrating anti-fibrotic effects with NV55 ...

5 April, 2017

Regulatory

NeuroVive’s lead NASH project to be presented at The International Liver Congress™

Lund, Sweden, April 5, 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that an abstract with preclinical data related to t ...

23 March, 2017

Regulatory

Notice of Annual General Meeting of Shareholders in NeuroVive Pharmaceutical AB

The Board of Directors of NeuroVive Pharmaceutical AB (publ) has issued a notice to the Annual General Meeting, which is to take place on Thursday, April 27, 2017, at 4 pm at Medicon Village, Scheelev ...

22 February, 2017

Regulatory

NeuroVive appoints recognized scientific advisors and enters research agreements in NASH and hepatocellular carcinoma

Lund, Sweden, February 22, 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced two new research agreements and the appointment ...